Netupitant and Palonosetron Hydrochloride and Zyprexa Zydis
Determining the interaction of Netupitant and Palonosetron Hydrochloride and Zyprexa Zydis and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using OLANZapine together with palonosetron can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval. In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between olanzapine and placebo in the proportion of patients experiencing potentially important changes in ECG parameters, including QT, QTcF (Fridericia-corrected), and PR intervals. In clinical trials, clinically meaningful QTc prolongations (QTcF >=500 msec at any time post-baseline in patients with baseline QTcF
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: netupitant / palonosetron
Brand name: Akynzeo
Synonyms: Netupitant and palonosetron, Netupitant and Palonosetron
Generic Name: olanzapine
Brand name: Zyprexa, Zyprexa Zydis, Zyprexa Intramuscular, Zyprexa Relprevv
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Netupitant and Palonosetron Hydrochloride-Zyrtec
- Netupitant and Palonosetron Hydrochloride-Zyrtec (Cetirizine Capsules and Tablets)
- Netupitant and Palonosetron Hydrochloride-Zyrtec (Cetirizine Chewable Tablets)
- Netupitant and Palonosetron Hydrochloride-Zyrtec (Cetirizine Orally Disintegrating Tablets)
- Netupitant and Palonosetron Hydrochloride-Zyrtec (Cetirizine Syrup)
- Netupitant and Palonosetron Hydrochloride-Zyrtec Capsule
- Zyprexa Zydis-Neuac
- Zyprexa Zydis-Neuac Gel
- Zyprexa Zydis-Neuac Kit
- Zyprexa Zydis-Neulasta
- Zyprexa Zydis-Neulasta Delivery Kit
- Zyprexa Zydis-Neulasta Onpro Kit